Multifaceted end points in brain tumor clinical trials: Cognitive deterioration precedes MRI progression

Neuro-Oncology

Volumn 5, Issue 2, 2003, Pages 89-95

  Meyers, Christina A ^a   Hess, Kenneth R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ASTROCYTOMA; BRAIN FUNCTION; BRAIN TUMOR; CANCER SURVIVAL; CLINICAL STUDY; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FEMALE; FUNCTIONAL ASSESSMENT; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; QUALITY OF LIFE; REGRESSION ANALYSIS; REVIEW; SCORING SYSTEM; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 0037388539     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-5-2-89     Document Type: Review

References (46)

1. Aiken, R.D. (1994) Quality-of-life issues in patients with malignant gliomas. Semin. Oncol. 21, 273-275.
2. Archibald, Y.M., Lunn, D., Ruttan, L.A., MacDonald, D.R., Del Maestro, R.F., Barr, H.W.K., Pexman, J.H.W., Fisher, B.J., Gaspar, L.E., and Cairncross, J.G. (1994) Cognitive functioning in long-term survivors of high-grade glioma. J. Neurosurg. 80, 247-253.
3. Benedict, R.H.B., Schretlen, D., Groninger, L., and Brandt, J. (1998) Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability. Clin. Neuropsychol. 12, 43-55.
4. Benton, A.L., and Hamsher, K.de S. (1989) Multilingual Aphasia Examination. Iowa City, Iowa: AJA Associates.
5. Brazil, L., Thomas, R., Laing, R,, Hines, F., Guerrero, D., Ashley, S., and Brada, M. (1997) Verbally administered Barthel Index as functional assessment in brain tumour patients. J. Neurooncol. 34, 187-192.
6. Browne, J.R, O'Boyle, C.A., McGee, H.M., Joyce, C.R., McDonald, N.J., O'Malley, K., and Hiltbrunner, B. (1994) Individual quality of life in the healthy elderly. Qual. Life Res. 3, 235-244.
7. Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S.B., Winicour, P., and Brannon, J. (1993) The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J. Clin. Oncol. 11, 570-577.
8. Choucair, A.K., Scott, C., Urtasun, R., Nelson, D., Mousas, B., and Curran, W. (1997) Quality of life and neuropsychological evaluation for patients with malignant astrocytomas: RTOG 91-14. Int. J. Radiat. Oncol. Biol. Phys. 38, 9-20.
9. DeAngelis, L.M., Delattre, J.-Y., and Posner, J.B. (1989) Radiation-induced dementia in patients cured of brain metastases. Neurology 39, 789-796.
10. Folstein, M.F., Folstein, S.E., and McHugh, P.R. (1975) "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198.
11. Grant, R., Slattery, J., Gregor, A,, and Whittle, I.R. (1994) Recording neurological impairment in clinical trials of glioma. J. Neurooncol. 19, 37-49.
12. Hess, K.R., Wong, E.T., Jaeckle, K.A., Kyritsis, A.P., Levin, VA., Prados, M.D., and Yung, W.K. (1999) Response and progression in recurrent malignant glioma. Neuro-oncol. 1, 282-288.
13. Hochberg, F.H., and Slotnick, B. (1980) Neuropsychologic impairment in astrocytoma survivors. Neurology 30, 172-177.
14. Hutchinson, T.A., Boyd, N.F., Feinstein, A.R., Gonda, A., Hollomby, D., and Rowat, B. (1979) Scientific problems in clinical scales, as demonstrated in the Karnofsky index of performance status. J. Chronic Dis. 32, 661-666.
15. Imperato, J.P., Paleologos, N.A., and Vick, N.A. (1990) Effects of treatment on long-term survivors with malignant astrocytomas. Ann. Neurol. 28, 818-822.
16. Jacobson, N.S., and Truax, P. (1991) Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. J. Consult. Clin. Psychol. 59, 12-19.
17. Karnofsky, D.A., and Burchenal, J.H. (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod, C.M. (Ed.), Evaluation of Chemotherapeutic Agents. New York: Columbia University Press, pp. 191-205.
18. Kleinberg, L., Wallner, K., and Malkin, M.G. (1993) Good performance status of long-term disease-free survivors of intracranial gliomas [erratum in Int. J. Radiat Oncol. Biol. Phys. 26, 563, 1993]. Int. J. Radiat. Oncol. Biol. Phys. 26, 129-133.
19. Leibel, S.A., Gutin, P.H., Wara, W.M., Silver, P.S., Larson, D.A., Edwards, M.S.B., Lamb, S.A., Ham, B., Weaver, K.A., Barnett, C., and Phillips, T.L. (1989) Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 17, 1129-1139.
20. Levin, V.A., Leibel, S., and Gutin, P.H. (1997) Neoplasms of the central nervous system. In: DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.), Cancer. Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers. pp. 2022-2082.
21. Lezak, M.D. (1995) Neuropsychological Assessment. 3rd ed. New York, Oxford University Press.
22. Lieberman, A.N., Foo, S,H., Ransohoff, J., Wise, A., George, A., Gordon, W., and Walker, R. (1982) Long term survival among patients with malignant brain tumors. Neurosurgery 10, 450-453.
23. Linacre, J.M., Heinemann, A.W., Wright, B.D., Granger, C.V., and Hamilton, B.B. (1994) The structure and stability of the Functional Independence Measure. Arch. Phys. Med. Rehabil. 75, 127-132.
24. Macdonald, D.R., Cascino, T.L., Schold, S.C., Jr., and Cairncross, J.G. (1990) Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280.
25. Mackworth, N., Fobair, P., and Prados, M.D. (1992). Quality of life self-reports from 200 brain tumor patients: Comparisons with Karnofsky performance scores. J. Neurooncol. 14, 243-253.
26. Meyers, C.A. (1997) Issues of quality of life in neuro-oncology. In. Vecht, C.J. (Vol. Ed.), Handbook of Clinical Neurology 23, Neuro-Oncology, Part 1. Brain Tumors: Principles of Biology, Diagnosis and Therapy. Amsterdam: Elsevier Science B.V., pp. 389-409.
27. Meyers, C.A., Grous, J.J., Ford, K.M., and Downing, G. (1996) Multifaceted models for assessing quality of life in brain cancer therapy trials. Drug Inf. J. 30, 856-857 (abstract).
28. Meyers, C.A., Mehta, M.P., Eisenberg, P., Schultz, C.J., Ford, J.M., Roa, W., Leibenhaut, M., Phan, S.C., and Renschler, M.F. (1999) Neurocognitive impairment in brain metastasis patients. Neuro-oncol. 1, 326 (abstract).
29. Meyers, C.A., Hess, K.R., Yung, W.K.A., and Levin, V.A. (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J. Clin. Oncol. 18, 646-650.
30. Meyers, C.A., Mehta, M.P., Rodrigus, P., Dehnad, H., Suh, J., Roa, W., Souhami, L., Bezjak, A., Komaki, R., Schultz, C., Timmerman, R., Curran, W.J., Meyers, S., Phan, S., Miller, R., Renschler, M.F., and Smith, J. (2002) Motexafin gadolinium (MGD) delays neurocognitive progression in patients with brain metastases from lung cancer: Results of a randomized Phase III trial. Neuro-oncol. 4, 372 (abstract).
31. Murray, K.J., Nelson, D.F., Scott, C., Fischbach, A.J., Porter, A., Farnan, N., and Curran, W.J. (1995) Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: A report of Radiation Therapy Oncology Group (RTOG) 83-02. Int. J. Radiat. Oncol. Biol. Phys. 31, 453-459.
32. National Cancer Institute and National Institute of Neurological Disorders and Stroke (2000). Report of the Brain Tumor Progress Review Group. Available at http://prg.nci.nih.gov/pdfprgreports/2000braintumor.pdf
33. O'Shaughnessy, J.A., Wittes, R.E., Burke, G., Friedman, M.A., Johnson, J.R., Niederhuber, J.E., Rothenberg, M.L., Woodcock, J., Chabner, B.A., and Temple, R. (1991) Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J. Clin. Oncol. 9, 2225-2232.
34. Osoba, D. (1994) Lessons learned from measuring health-related quality of life in oncology. J. Clin. Oncol. 12, 608-616.
35. Sachsenheimer, W., Piotrowski, W., and Bimmler, T. (1992) Quality of life in patients with intracranial tumors on the basis of Karnofsky's performance status. J. Neurooncol. 13, 177-181.
36. Salander, P., Karlsson, T., Bergenheim, T., and Henriksson, R. (1995) Long-term memory deficits in patients with malignant gliomas. J. Neurooncol. 25, 227-238.
37. Scerrati, M., Montemaggi, P., Iacoangeli, M., Roselli, R., and Rossi, G.F. (1994). Interstitial brachytherapy for low-grade cerebral gliomas: Analysis of results in a series of 36 cases. Acta Neurochir. 131, 97-105.
38. Scheibel, R.S., Meyers, C.A., and Levin, V.A. (1996) Cognitive dysfunction following surgery for intracerebral glioma: Influence of histopathology, lesion location, and treatment. J. Neurooncol. 30, 61-69.
39. Scott, C.B. Quality-adjusted survival analysis of malignant glioma patients. Control. Clin. Trials 18, 277-285.
40. Sneeuw, K.C.A., Aaronson, N.K., Osoba, D., Muller, M.J., Hsu, M.A., Yung, W.K., Brada, M., and Newlands, E.S. (1997) The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med. Care 35, 490-560.
41. Taphoorn, M.J.B., Schiphorst, A.K., Snoek, J.F., Lindeboom, J., Wolbers, J.G., Karim, A.B.M.F., Huijgens, P.C., and Heimans, J.J. (1994) Cognitive functions and quality of life in patients with low-grade gliomas: The impact of radiotherapy. Ann. Neurol. 36, 48-54.
42. Trojanowski, T., Peszynski, J., Turowski, K., Markiewicz P., Goscinski, I., Bielawski, A., Bendarzewska, B., Szymona, J., Dabrowska, A., Lopatkiewicz, J., Czochra, T., Jeziernicka, B., Basinska, G., and Kozniewska, H. (1989) Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy. J. Neurosurg. 70, 18-23.
43. Wade, D.T. (1992) Measurement in Neurological Rehabilitation. New York: Oxford University Press, pp. 236-237.
44. Wechsler D. (1981) Wechsler Adult Intelligence Scale - Revised. San Antonio: The Psychological Corporation.
45. Weitzner, M.A., Meyers, C.A., Gelke, C.K., Byrne, K.S., Cella, D.F., and Levin, VA. (1995) The Functional Assessment of Cancer Therapy (FACT) scale: Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75, 1151-1161.
46. World Health Organization. (1980) International Classification of Impairments, Disabilities, and Handicaps. Geneva: World Health Organization.